The use of orthokine therapy for the treatment of post refractive surgery corneal ulcer, a case report.
暂无分享,去创建一个
[1] G. Qin,et al. Efficacy and safety of anti-interleukin-1 therapeutics in the treatment of knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials , 2023, Journal of Orthopaedic Surgery and Research.
[2] Evan. The Biologic Approach for Managing Cartilage Injury: Where are We Now™ , 2023, Orthopaedic Journal of Sports Medicine.
[3] S. Dow,et al. In Vitro Anti-Inflammatory and Regenerative Effects of Autologous Conditioned Serum from Dogs with Osteoarthritis , 2022, Animals : an open access journal from MDPI.
[4] M. Yousefi,et al. The therapeutic effects of autologous conditioned serum on knee osteoarthritis: an animal model , 2022, BMC research notes.
[5] S. Shakouri,et al. Autologous conditioned serum (Orthokine) injection for treatment of classical trigeminal neuralgia: results of a single-center case series , 2022, Journal of Medical Case Reports.
[6] R. Sitompul,et al. Amniotic membrane transplantation for infectious corneal ulcer treatment: a cohort retrospective study , 2020, Medical Journal of Indonesia.
[7] Afsaneh Vazin,et al. A study on the most prevalent bacterial cause of corneal ulcer and their susceptibility to five common types of ophthalmic antibiotics , 2020 .
[8] D. Golicki,et al. Evaluation of the Effectiveness of Orthokine Therapy: Retrospective Analysis of 1000 Cases. , 2020, Ortopedia, traumatologia, rehabilitacja.
[9] R. Porter,et al. Interleukin-1 receptor antagonist (IL-1Ra) is more effective in suppressing cytokine-induced catabolism in cartilage-synovium co-culture than in cartilage monoculture , 2019, Arthritis Research & Therapy.
[10] Bing Zhang,et al. IL-1β receptor antagonist (IL-1Ra) combined with autophagy inducer (TAT-Beclin1) is an effective alternative for attenuating extracellular matrix degradation in rat and human osteoarthritis chondrocytes , 2019, Arthritis Research & Therapy.
[11] N. Damjanov,et al. The efficacy and safety of autologous conditioned serum (ACS) injections compared with betamethasone and placebo injections in the treatment of chronic shoulder joint pain due to supraspinatus tendinopathy: a prospective, randomized, double-blind, controlled study. , 2018, Medical ultrasonography.
[12] L. Tártara,et al. Treatment of corneal ulcers with platelet rich plasma , 2014 .
[13] S. Masiero,et al. Autologous conditioned serum for the treatment of osteoarthritis and other possible applications in musculoskeletal disorders. , 2013, British medical bulletin.
[14] C. Botsios. Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases. , 2005, Autoimmunity reviews.
[15] P. Wehling,et al. Treatment of muscle injuries by local administration of autologous conditioned serum: a pilot study on sportsmen with muscle strains. , 2004, International journal of sports medicine.
[16] Xiaoling Zhang,et al. Suppression of early experimental osteoarthritis by gene transfer of interleukin‐1 receptor antagonist and interleukin‐10 , 2004, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[17] P. Wehling,et al. The production of anti-inflammatory cytokines in whole blood by physico-chemical induction , 2003, Inflammation Research.
[18] V. Durairaj,et al. Infectious keratitis after laser refractive surgery. , 2001, Ophthalmology.
[19] M. Srinivasan,et al. Corneal ulceration in the developing world—a silent epidemic , 1997, The British journal of ophthalmology.
[20] N. Srivastava,et al. “Etiology, Risk Factor, Diagnosis and Treatment Outcome of Fungal Corneal Ulcer in Tertiary Care Centre” , 2020 .
[21] M. Abbasian,et al. Comparison of the Effect of Intra-Articular Injection of Autologous (Orthokine) Interleukin-1 Receptor Antagonist (IL-1Ra) and Hyaluronic Acid in Pain Control of Knee Osteoarthritis , 2019 .
[22] M.L.V. de Mello,et al. Treatment of Corneal Ulcer Complicated In Domestic Canine, With the Complementary Use of Homeopathy, Moxabustion and Autologous Serum , 2018 .
[23] C. McIlwraith,et al. Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene , 2002, Gene Therapy.